8-hydroxy-2-(di-n-propylamino)tetralin has been researched along with Idiopathic Parkinson Disease in 15 studies
8-Hydroxy-2-(di-n-propylamino)tetralin: A serotonin 1A-receptor agonist that is used experimentally to test the effects of serotonin.
8-OH-DPAT : A tetralin substituted at positions 1 and 7 by hydroxy and dipropylamino groups respectively
| Excerpt | Relevance | Reference |
|---|---|---|
| "We hypothesized that hyperalgesia of 6-OHDA rats may be related to increased excitability of SDH neurons, and functional change of 5-HT3 receptor may reverse the hyperalgesia of 6-OHDA lesioned rats and decrease cell excitability of SDH neurons." | 1.72 | Inhibition of Spinal 5-HT3 Receptor and Spinal Dorsal Horn Neuronal Excitability Alleviates Hyperalgesia in a Rat Model of Parkinson's Disease. ( An, MQ; Dai, YP; Dong, LG; Gu, HY; Li, CJ; Liu, CF; Liu, LB; Mao, CJ; Wang, F; Zhang, LG, 2022) |
| "Depression is one of the most common neuropsychiatric disturbances in Parkinson's disease (PD), but its pathophysiology is not definite." | 1.56 | Involvement of the Dorsal Hippocampus 5-HT1A Receptors in the Regulation of Depressive-Like Behaviors in Hemiparkinsonian Rats. ( Guo, Y; Hu, W; Jiang, YF; La, XM; Liu, J; Wang, HS; Xie, W; Yang, J; Zhang, J; Zhang, L, 2020) |
| "The results suggest that compounds that indirectly facilitate 5-HT1 A receptor activation, such as citalopram, may be more effective therapeutics than direct 5-HT1 A receptor agonists because they exhibit similar anti-dyskinesia efficacy, while possessing a reduced side effect profile." | 1.42 | Side effect profile of 5-HT treatments for Parkinson's disease and L-DOPA-induced dyskinesia in rats. ( Bishop, C; Conti, MM; Lindenbach, D; Ostock, CY; Palumbo, N; Vilceus, N, 2015) |
| "Motor symptoms of Parkinson's disease are commonly treated using l-DOPA although long-term treatment usually causes debilitating motor side effects including dyskinesias." | 1.39 | Effects of 5-HT1A receptor stimulation on striatal and cortical M1 pERK induction by L-DOPA and a D1 receptor agonist in a rat model of Parkinson's disease. ( Bishop, C; Dupre, KB; Eskow Jaunarajs, KL; Goldenberg, AA; Lindenbach, D; Ostock, CY, 2013) |
| " Furthermore, chronic administration of low doses of the 5-HT(1) agonists in combination was able to prevent development of dyskinesia, and reduce the up-regulation of FosB after daily treatment with l-DOPA in the rat 6-OHDA model." | 1.35 | Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia. ( Bezard, E; Björklund, A; Carlsson, T; Carta, M; Di Luca, M; Gardoni, F; Kirik, D; Li, Q; Marcello, E; Muñoz, A; Qin, C, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (6.67) | 18.2507 |
| 2000's | 6 (40.00) | 29.6817 |
| 2010's | 6 (40.00) | 24.3611 |
| 2020's | 2 (13.33) | 2.80 |
| Authors | Studies |
|---|---|
| Li, CJ | 1 |
| Zhang, LG | 1 |
| Liu, LB | 1 |
| An, MQ | 1 |
| Dong, LG | 1 |
| Gu, HY | 1 |
| Dai, YP | 1 |
| Wang, F | 1 |
| Mao, CJ | 1 |
| Liu, CF | 1 |
| Liu, Y | 1 |
| Liu, J | 3 |
| Jiao, SR | 1 |
| Liu, X | 1 |
| Guo, Y | 2 |
| Zhang, J | 2 |
| Yang, J | 2 |
| Xie, W | 2 |
| Wang, HS | 2 |
| Zhang, L | 2 |
| Jiang, YF | 1 |
| Hu, W | 1 |
| La, XM | 1 |
| Miyazaki, I | 1 |
| Asanuma, M | 1 |
| Murakami, S | 1 |
| Takeshima, M | 1 |
| Torigoe, N | 1 |
| Kitamura, Y | 1 |
| Miyoshi, K | 1 |
| Lindenbach, D | 2 |
| Dupre, KB | 2 |
| Eskow Jaunarajs, KL | 1 |
| Ostock, CY | 2 |
| Goldenberg, AA | 1 |
| Bishop, C | 3 |
| Hui, YP | 1 |
| Wang, T | 1 |
| Han, LN | 1 |
| Li, LB | 1 |
| Sun, YN | 1 |
| Qiao, HF | 1 |
| Zhang, QJ | 1 |
| Palumbo, N | 1 |
| Vilceus, N | 1 |
| Conti, MM | 1 |
| Eskow, KL | 1 |
| Barnum, CJ | 1 |
| Sharp, SI | 1 |
| Ballard, CG | 1 |
| Ziabreva, I | 1 |
| Piggott, MA | 1 |
| Perry, RH | 1 |
| Perry, EK | 1 |
| Aarsland, D | 1 |
| Ehrt, U | 1 |
| Larsen, JP | 1 |
| Francis, PT | 2 |
| Muñoz, A | 1 |
| Li, Q | 1 |
| Gardoni, F | 1 |
| Marcello, E | 1 |
| Qin, C | 1 |
| Carlsson, T | 1 |
| Kirik, D | 1 |
| Di Luca, M | 1 |
| Björklund, A | 1 |
| Bezard, E | 1 |
| Carta, M | 1 |
| Nahimi, A | 1 |
| Høltzermann, M | 1 |
| Landau, AM | 1 |
| Simonsen, M | 1 |
| Jakobsen, S | 1 |
| Alstrup, AK | 1 |
| Vang, K | 1 |
| Møller, A | 1 |
| Wegener, G | 1 |
| Gjedde, A | 1 |
| Doudet, DJ | 1 |
| Mignon, LJ | 1 |
| Wolf, WA | 2 |
| Tomiyama, M | 1 |
| Kimura, T | 1 |
| Maeda, T | 1 |
| Kannari, K | 1 |
| Matsunaga, M | 1 |
| Baba, M | 1 |
| Mignon, L | 1 |
| Chen, CP | 1 |
| Alder, JT | 1 |
| Bray, L | 1 |
| Kingsbury, AE | 1 |
| Foster, OJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Role of Sleep Homeostasis in the Development of the L-Dopa Induced Dyskinesias in Patients With Parkinson's Disease[NCT02200887] | 48 participants (Actual) | Observational | 2013-09-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
15 other studies available for 8-hydroxy-2-(di-n-propylamino)tetralin and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
Inhibition of Spinal 5-HT3 Receptor and Spinal Dorsal Horn Neuronal Excitability Alleviates Hyperalgesia in a Rat Model of Parkinson's Disease.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Dopamine; Hyperalgesia; Ondansetron; Oxidopamine; P | 2022 |
Serotonin
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Disease Models, Animal; Dopamine; Habituation, Psyc | 2019 |
Involvement of the Dorsal Hippocampus 5-HT1A Receptors in the Regulation of Depressive-Like Behaviors in Hemiparkinsonian Rats.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Amygdala; Animals; Behavior, Animal; Depression; Disease Mod | 2020 |
Targeting 5-HT(1A) receptors in astrocytes to protect dopaminergic neurons in Parkinsonian models.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Adrenergic Agents; Animals; Astrocytes; Brain; Buspirone; Ce | 2013 |
Effects of 5-HT1A receptor stimulation on striatal and cortical M1 pERK induction by L-DOPA and a D1 receptor agonist in a rat model of Parkinson's disease.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Corpus Striatum; Disease Models, Animal; Extracellu | 2013 |
Anxiolytic effects of prelimbic 5-HT(1A) receptor activation in the hemiparkinsonian rat.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Anti-Anxiety Agents; Anxiety; Disease Models, Anima | 2015 |
Side effect profile of 5-HT treatments for Parkinson's disease and L-DOPA-induced dyskinesia in rats.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antiparkinson Agents; Buspirone; Citalopram; Dyskin | 2015 |
Striatal 5-HT1A receptor stimulation reduces D1 receptor-induced dyskinesia and improves movement in the hemiparkinsonian rat.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Adrenergic Agents; Animals; Benzazepines; Biogenic Monoamine | 2008 |
Cortical serotonin 1A receptor levels are associated with depression in patients with dementia with Lewy bodies and Parkinson's disease dementia.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Aged; Aged, 80 and over; Antidepressive Agents; Antiparkinso | 2008 |
Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antip | 2008 |
Serotonergic modulation of receptor occupancy in rats treated with L-DOPA after unilateral 6-OHDA lesioning.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Analysis of Variance; Animals; Antiparkinson Agents; Autorad | 2012 |
8-hydroxy-2-(di-n-propylamino)tetralin reduces striatal glutamate in an animal model of Parkinson's disease.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Aspartic Acid; Corpus Striatum; Denervation; Diseas | 2005 |
A serotonin 5-HT1A receptor agonist prevents behavioral sensitization to L-DOPA in a rodent model of Parkinson's disease.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antiparkinson Agents; Behavior, Animal; Corpus Stri | 2005 |
Postsynaptic 5-HT1A receptor stimulation increases motor activity in the 6-hydroxydopamine-lesioned rat: implications for treating Parkinson's disease.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Analysis of Variance; Animals; Behavior, Animal; Brain Chemi | 2007 |
Post-synaptic 5-HT1A and 5-HT2A receptors are increased in Parkinson's disease neocortex.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Humans; Ketanserin; Kinetics; Neocortex; Parkinson Disease; | 1998 |